免疫系を備えた「肺オンチップ」技術が疾患研究に新展開(Breathtaking Breakthrough: Lung-on-a-Chip Defends Itself)

ad

2025-09-24 ジョージア工科大学(Georgia Tech)

ジョージア工科大学とヴァンダービルト大学の研究チームは、世界初の「免疫系を備えた肺オンチップ」を開発しました。従来のオルガンチップでは免疫細胞が長く生存せず実際の感染応答を再現できませんでしたが、本研究では血液・免疫細胞が循環し、生体肺と同様にインフルエンザ感染に対する炎症や防御反応を示すことを実証しました。この成果はNature Biomedical Engineeringに掲載され、喘息、嚢胞性線維症、肺がん、結核など多様な疾患研究にも応用可能とされています。将来的には患者由来細胞を用いた個別化医療チップの開発や、動物実験代替モデルとしての利用が期待されています。

免疫系を備えた「肺オンチップ」技術が疾患研究に新展開(Breathtaking Breakthrough: Lung-on-a-Chip Defends Itself)
Ankur Singh and Rachel Ringquist point to the microscopic lung-on-a-chip that has a built-in immune system.

<関連情報>

ヒトの重症インフルエンザ感染反応をモデル化するための免疫応答性肺チップ An immune-competent lung-on-a-chip for modelling the human severe influenza infection response

Rachel Ringquist,Eshant Bhatia,Paramita Chatterjee,Drishti Maniar,Zhou Fang,Page Franz,Liana Kramer,Delta Ghoshal,Neha Sonthi,Emma Downey,Joshua Canlas,Abigail Ochal,Savi Agarwal,Valeria Cuéllar,Grace Harrigan,Ahmet F. Coskun,Ankur Singh & Krishnendu Roy
Nature Biomedical Engineering  Published:23 September 2025
DOI:https://doi.org/10.1038/s41551-025-01491-9

Abstract

Severe influenza affects 3–5 million people worldwide each year, resulting in more than 300,000 deaths annually. However, standard-of-care antiviral therapeutics have limited effectiveness in these patients. Current preclinical models of severe influenza fail to accurately recapitulate the human immune response to severe viral infection. Here we develop an immune-competent, microvascularized, human lung-on-a-chip device to model the small airways, successfully demonstrating the cytokine storm, immune cell activation, epithelial cell damage, and other cellular- and tissue-level human immune responses to severe H1N1 infection. We find that interleukin-1β and tumour necrosis factor-α play opposing roles in the initiation and regulation of the cytokine storm associated with severe influenza. Furthermore, we discover the critical stromal–immune CXCL12–CXCR4 interaction and its role in immune response to infection. Our results underscore the importance of stromal cells and immune cells in microphysiological models of severe lung disease, describing a scalable model for severe influenza research. We expect the immune-competent human lung-on-a-chip device to enable critical discoveries in respiratory host–pathogen interactions, therapeutic side effects, vaccine potency evaluation, and crosstalk between systemic and mucosal immunity in human lung.

医療・健康
ad
ad
Follow
ad
タイトルとURLをコピーしました